Key Insights

Highlights

Success Rate

83% trial completion

Published Results

421 trials with published results (21%)

Research Maturity

1176 completed trials (57% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

11.8%

243 terminated out of 2052 trials

Success Rate

82.9%

-3.7% vs benchmark

Late-Stage Pipeline

9%

176 trials in Phase 3/4

Results Transparency

36%

421 of 1176 completed with results

Key Signals

421 with results83% success243 terminated

Data Visualizations

Phase Distribution

1,754Total
Not Applicable (249)
Early P 1 (21)
P 1 (667)
P 2 (641)
P 3 (154)
P 4 (22)

Trial Status

Completed1,176
Terminated243
Unknown231
Recruiting187
Withdrawn89
Active Not Recruiting76

Trial Success Rate

82.9%

Benchmark: 86.5%

Based on 1176 completed trials

Clinical Trials (2052)

Showing 20 of 20 trials
NCT07524530Phase 2Not Yet Recruiting

Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers

NCT02465060Phase 2Active Not Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT03696784Phase 1Active Not RecruitingPrimary

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

NCT07628634Early Phase 1Recruiting

Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors

NCT07739849Not ApplicableNot Yet Recruiting

Flow on FNA/Core Project- Faster Diagnosis for Lymphoma: Utilising Flow Cytometry on FNA Samples of Lymph Nodes to Diagnose Lymphoma in Hours, Not Days.

NCT06218602Phase 2RecruitingPrimary

Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.

NCT03264131Phase 2CompletedPrimary

BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma

NCT07015242Phase 2RecruitingPrimary

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

NCT00352924Active Not Recruiting

Agriculture Health Study

NCT01441089Recruiting

Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis

NCT03258567Phase 2Recruiting

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

NCT03223610Phase 1RecruitingPrimary

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

NCT04898790Not ApplicableRecruiting

Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant

NCT05135351Not ApplicableRecruiting

Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Cellular Therapy

NCT07621887Not ApplicableNot Yet Recruiting

Digitalized Exercise Fit Tool Intervention for Adolescents With Blood Cancer

NCT07654426Phase 2Recruiting

The CARDIOPROTECT Trial

NCT05170399Phase 4RecruitingPrimary

Vaccine Responses in Patients With B Cell Malignancies

NCT04570423Phase 2Recruiting

A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

NCT06563505Phase 2RecruitingPrimary

A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma

NCT05346809Phase 2Active Not RecruitingPrimary

Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma

Scroll to load more

Research Network

Activity Timeline